Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The burden of treatment-resistant depression: A systematic review of the economic and quality of life literature
Karissa Johnston, Lauren Powell, Ian Anderson, et al.
Journal of Affective Disorders (2018) Vol. 242, pp. 195-210
Closed Access | Times Cited: 254

Showing 1-25 of 254 citing articles:

Melatonin Attenuates LPS-Induced Acute Depressive-Like Behaviors and Microglial NLRP3 Inflammasome Activation Through the SIRT1/Nrf2 Pathway
Burak I. Ariöz, Bora Tastan, Emre Tarakcioglu, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 398
The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study
Dena H. Jaffe, Benoît Rive, Tom Denee
BMC Psychiatry (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 184
Long-Term Outcomes of Subcallosal Cingulate Deep Brain Stimulation for Treatment-Resistant Depression
Andrea Crowell, Patricio Riva‐Posse, Paul E. Holtzheimer, et al.
American Journal of Psychiatry (2019) Vol. 176, Iss. 11, pp. 949-956
Open Access | Times Cited: 145
Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life
Guy M. Goodwin, Scott T. Aaronson, Oscar Alvarez, et al.
Journal of Affective Disorders (2023) Vol. 327, pp. 120-127
Open Access | Times Cited: 93
Vitamin D and Depression: A Critical Appraisal of the Evidence and Future Directions
Vikas Menon, Sujita Kumar Kar, Navratan Suthar, et al.
Indian Journal of Psychological Medicine (2019) Vol. 42, Iss. 1, pp. 11-21
Open Access | Times Cited: 140
Transcranial Magnetic Stimulation for Pain, Headache, and Comorbid Depression: INS-NANS Expert Consensus Panel Review and Recommendation
Albert Leung, Prasad Shirvalkar, Robert Chen, et al.
Neuromodulation Technology at the Neural Interface (2020) Vol. 23, Iss. 3, pp. 267-290
Closed Access | Times Cited: 87
Depression: Biological markers and treatment
Gordana Nedić Erjavec, Marina Šagud, Matea Nikolac Perković, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020) Vol. 105, pp. 110139-110139
Closed Access | Times Cited: 85
Magnitude of the Placebo Response Across Treatment Modalities Used for Treatment-Resistant Depression in Adults
Brett D. M. Jones, Laís B. Razza, Cory R. Weissman, et al.
JAMA Network Open (2021) Vol. 4, Iss. 9, pp. e2125531-e2125531
Open Access | Times Cited: 84
The assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF)
Harold A. Sackeïm, Scott T. Aaronson, Mark Bunker, et al.
Journal of Psychiatric Research (2019) Vol. 113, pp. 125-136
Open Access | Times Cited: 82
Polyphenols selectively reverse early-life stress-induced behavioural, neurochemical and microbiota changes in the rat
Francisco Donoso, Sian Egerton, Thomaz F. S. Bastiaanssen, et al.
Psychoneuroendocrinology (2020) Vol. 116, pp. 104673-104673
Open Access | Times Cited: 71
The neurobiology of treatment-resistant depression: A systematic review of neuroimaging studies
Nora Runia, Dilan E. Yücel, Anja Lok, et al.
Neuroscience & Biobehavioral Reviews (2021) Vol. 132, pp. 433-448
Open Access | Times Cited: 68
Targeting neuroinflammation by polyphenols: A promising therapeutic approach against inflammation-associated depression
Mohammed Abu Tayab, Mohammad Nazmul Islam, Kazi Ashfak Ahmed Chowdhury, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 147, pp. 112668-112668
Open Access | Times Cited: 62
Gut microbiome: A potential indicator for predicting treatment outcomes in major depressive disorder
Zaiquan Dong, Xiaoling Shen, Yanni Hao, et al.
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 46
Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme
Ludovic Samalin, Maud Rothärmel, Lila Mékaoui, et al.
International Journal of Psychiatry in Clinical Practice (2022) Vol. 26, Iss. 4, pp. 352-362
Open Access | Times Cited: 38
Economic Cost of Functional Neurologic Disorders
Brian O’Mahony, Glenn Nielsen, Sallie Baxendale, et al.
Neurology (2023) Vol. 101, Iss. 2
Open Access | Times Cited: 35
Pre-treatment predictors of cognitive side-effects after treatment with electroconvulsive therapy in patients with depression: A multicenter study
Dore Loef, Philip van Eijndhoven, Eva van den Munckhof, et al.
Journal of Affective Disorders (2024) Vol. 349, pp. 321-331
Open Access | Times Cited: 10
Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK
Anthony J. Cleare, Jess Kerr‐Gaffney, Kimberley Goldsmith, et al.
The Lancet Psychiatry (2025) Vol. 12, Iss. 4, pp. 276-288
Open Access | Times Cited: 1
All-cause mortality in patients with treatment-resistant depression: a cohort study in the US population
Gang Li, Daniel Fife, Grace Wang, et al.
Annals of General Psychiatry (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 68
Anti-Inflammatory Activity of Melatonin: a Focus on the Role of NLRP3 Inflammasome
Milad Ashrafizadeh, Masoud Najafi, Nasim Kavyiani, et al.
Inflammation (2021) Vol. 44, Iss. 4, pp. 1207-1222
Closed Access | Times Cited: 48
Epidemiology and costs of depressive disorder in Spain: the EPICO study
Eduard Vieta, Jordi Alonso, Víctor Pérez, et al.
European Neuropsychopharmacology (2021) Vol. 50, pp. 93-103
Open Access | Times Cited: 44
Population-attributable risk of adverse childhood experiences for high suicide risk, psychiatric admissions, and recurrent depression, in depressed outpatients
Sergio Gloger, Pablo Martínez, Alex Behn, et al.
European journal of psychotraumatology (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 43
Next-Generation Personalized Medicine: Implementation of Variability Patterns for Overcoming Drug Resistance in Chronic Diseases
Yaron Ilan
Journal of Personalized Medicine (2022) Vol. 12, Iss. 8, pp. 1303-1303
Open Access | Times Cited: 33
Care pathways for people with major depressive disorder: A European Brain Council Value of Treatment study
Rebecca Strawbridge, Paul McCrone, Andrea Ulrichsen, et al.
European Psychiatry (2022) Vol. 65, Iss. 1
Open Access | Times Cited: 30
Subjective and objective sleep and circadian parameters as predictors of depression-related outcomes: A machine learning approach in UK Biobank
Laura M. Lyall, Natasha Sangha, Xingxing Zhu, et al.
Journal of Affective Disorders (2023) Vol. 335, pp. 83-94
Open Access | Times Cited: 21
Quercetin abrogates lipopolysaccharide-induced depressive-like symptoms by inhibiting neuroinflammation via microglial NLRP3/NFκB/iNOS signaling pathway
Olusegun Adebayo Adeoluwa, Juliet N. Olayinka, Gladys Onyinye Adeoluwa, et al.
Behavioural Brain Research (2023) Vol. 450, pp. 114503-114503
Closed Access | Times Cited: 21
Page 1 - Next Page

Scroll to top